Poultry Vaccines Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccine (Inactivated Vaccines, Live Attenuated Vaccines, and Others), By Application (Mareka's Disease, Newcastle Disease, Infectious Bursal Disease, Infectious Bronchitis, Avian Influenza, Coccidiosis, Mycoplasma, and Others), and Region Forecast 2020-2031

Poultry Vaccines Market size was valued at US$ 2.2 billion in 2024 and is expected to reach US$ 3.3 billion by 2031, growing at a significant CAGR of  5.9% from 2025-2031. The disease outbreaks in poultry drive the poultry vaccine market. Growing farmed poultry can speed up the spread of infectious pathogens among birds, such as the avian influenza virus, which has the great promise to cause widespread mortality and significant economic losses in poultry. However, poultry is accepted as a good source of protein.

The poultry industry will be forced to intensify production in many countries, leading to more significant numbers of farms that house birds at elevated densities. Hence the regulatory bodies are accelerating the approval process for various vaccines related to veterinary health. Increasing awareness among veterinary practitioners about animal vaccination, growing meat consumption, and rising government initiatives for food safety is boosting the market. The growing poultry population, combined with the rising prevalence of avian diseases, will also drive market growth in the coming years.

Moreover, infected meat consumption risks human health, thereby making it imperative that the birds be vaccinated before usage. The main obstacles poultry farms face are the rapid spread of diseases and the lack of treatment options. To prevent such situations, vaccination becomes mandatory. In 2021, the attenuated live vaccines segment held the largest revenue share. Live attenuated vaccines' duration of immunity lasts longer and protects against avian diseases such as infectious bronchitis, infectious bursal disease, and Newcastle disease. Moreover, growing R&D activities, particularly in this field of vaccination, to curb various outbreaks of the diseases mentioned above are accentuating the segment growth.

Key Developments

• In March 2025, France announced that poultry flocks could be kept outdoors again following a decline in bird flu infections, which the government credited to its nationwide vaccination program. In 2023, France became the first major poultry exporter to implement a nationwide avian influenza vaccination campaign to combat the highly pathogenic virus. This initiative aimed to protect poultry flocks, curb outbreaks, and prevent the virus from spreading to other species, including humans. The success of this program highlights the effectiveness of large-scale vaccination in controlling avian influenza.
• In February 2025, Boehringer Ingelheim will launch VAXXITEK® HVT+IBD+H5 in Egypt, expanding its VAXXITEK® range with protection against Marek’s disease, Infectious Bursal Disease, and H5 avian influenza. Manufactured in the U.S. and licensed since 2023, the vaccine reflects the company’s expertise in avian influenza protection. However, avian influenza vaccination remains prohibited in the U.S.
• In November 2024, Boehringer Ingelheim launched a next-generation Marek’s disease vaccine in India, offering enhanced protection through a controlled attenuation process. Recommended for in-ovo and one-day-old chick vaccination, it ensures an optimal balance of safety and efficacy. With Marek’s disease still a major threat in Indian poultry, this serotype-1 construct vaccine addresses gaps in existing prevention strategies.
• In February 2021, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA announced the completion of its acquisition of PrognostiX Poultry Limited d/b/a Poultry Sense Ltd. from its founding shareholders.
• In July 2020, Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health. For instance, in April 2019, according to the Middle East Rating Agency, the Qatar government established central food laboratories with different procedures and analyses on food safety to ensure consumers are provided with contamination-free, safe, and high-quality meat products.

Poultry Vaccine Market Segmentation:

Based on vaccine type:

• Inactivated Vaccines
• Live Attenuated Vaccines
• Others

Inactivated vaccines hold the leading share in the Poultry Vaccines Market, driven by their high safety profile and strong immune response without the risk of reverting to virulence. These vaccines are widely used for controlling severe poultry diseases such as avian influenza, Newcastle disease, and infectious bursal disease (IBD). Their ability to provide long-lasting immunity and stability makes them a preferred choice for commercial poultry farms. Additionally, advancements in adjuvant formulations have enhanced their efficacy, further boosting adoption. Governments and poultry producers favor inactivated vaccines for mass immunization programs, ensuring flock protection while maintaining productivity in the growing poultry industry.

Based on application:

• Mareks Disease
• Newcastle Disease
• Infectious Bursal Disease
• Infectious Bronchitis
• Avian Influenza
• Coccidiosis
• Mycoplasma
• Others

Newcastle Disease holds the leading share in the Poultry Vaccines Market, driven by its high prevalence and severe impact on poultry production worldwide. As a highly contagious viral disease, it causes significant mortality and economic losses, making vaccination a critical preventive measure. Governments and poultry producers prioritize Newcastle disease vaccination to ensure flock health and maintain poultry trade regulations. Both inactivated and live attenuated vaccines are widely used, with routine immunization programs mandated in many countries. Additionally, advancements in vector-based vaccines are improving protection against Newcastle disease while offering combined immunity against other poultry infections, further driving market growth.